Common Stock, $0.0001 par value per share
- Symbol
- OCUL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Ocular Therapeutix, Inc.
OCULNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph. D., Chief Strategy Officer of Ocular Therapeutix, Inc.…
Company context
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Current securities
Registered securities in this filing
OCULAR THERAPEUTIX, INC. · 8-K · Filed 2026-10-16
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph. D.,
Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company,
effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.